NEW YORK, July 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
World Pain Relieving Drug Market 2011-2021
http://www.reportlinker.com/p0572964/World-Pain-Relieving-Drug-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
We show you revenue growth opportunities there
What are the prospects for the pain treatment market from 2011? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that pharma industry and market.
Our report gives you revenue forecasts to 2021 for pain-relieving drugs. You will discover market predictions at total world, submarket, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions.
You will see forecasts for 21 leading pain-relieving drugs to 2021. We discuss Pfizer, J&J, GSK, Novartis, Bayer and many other companies. There are good market opportunities for original and generic drugs from 2011, we conclude.
We cover narcotic and non-narcotic pain reliever, arthritic pain reliever and anti-migraine markets. We also cover neuropathic pain relievers and local anaesthetics. You will see discussions of marketed drugs and those in development. There is a strong R&D pipeline.
We help you to assess the pain treatment industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see what its future holds.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, product discussions, an R&D review and opinions from our survey.
We include 122 tables and charts and two research interviews (shown in the accompanying lists). We help you to stay ahead in knowledge for this industry and market.
World Pain Relieving Drug Market 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
• You will receive hard data for the pain treatment industry and market - especially our revenue forecasts to 2021
• You will discover revenue predictions to 2021 for the overall market and its main components - seeing where the highest revenue growth will occur
• You will see revenue prospects to 2021 for 21 leading products, with discussions of market potential and competition
• You will find revenue prospects to 2021 for leading national markets (US,Japan, UK, Germany, France, Spain, Italy, China and India)
• You will learn how the pain treatment industry can change from 2011 to 2021
• You will assess leading companies providing pain-relieving drugs, discovering their activities, outlooks and revenue prospects
• You will investigate competition and opportunities influencing the industry and market from 2011 onwards
• You will see what will stimulate and restrain the industry and market from 2011
• You will review pain treatment technologies, assessing pharma R&D potential
• You will investigate commercial requirements - with therapeutic needs and sales opportunities discussed
• You will analyse opportunities for established companies and those seeking to enter the anti-pain drugs market
• You will view opinions from our survey, including full interview transcripts.
That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for pain treatments.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in the pain relief industry and market. We give predictions and answers you need. Don't miss out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Table of Contents
1. Executive Summary
1.1 The Pain Relieving Drug Market: Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Introduction to the Global Pain Relieving Drug Market
2.1 What is Pain?
2.1.1 Historical Aspects of Pain
2.2 Pain Pathways
2.2.1 The WHO Pain Ladder
2.3 Classification and Types of Pain
2.3.1 Acute Pain
2.3.2 Chronic Pain
2.3.3 Psychological Effects of Chronic Pain
2.3.4 The Financial Burden of Chronic Pain
2.3.5 Chronic Cancer Pain
2.4 Neuropathic Pain
2.4.1 Distinguishing Neuropathic Pain
2.5 Neurochemistry of Pain
2.5.1 Prostaglandins
2.5.2 Opioids
2.6 Pain Treatments
2.6.1 Opioids for the Treatment of Pain
2.6.2 Consequences of Opioids
2.6.3 Treating Addiction to Prescription Opioids
2.7 OTC Pain Relievers
3. The Global Pain Relieving Drug Market, 2011-2021
3.1 The Global Pain Market: Analysis and Forecast, 2011-2021
3.2 Sub Market Categories of the World Pain Drug Market
3.2.1 Oxycontin: Current Market Leader
3.2.2 The Anti-Epileptics Segment Will Retain Market Dominance
3.3 Success in the Global Pain Treatment Market Has Been Challenging
3.4 The Pain Relieving Drug Market Will Grow in the Near Future
4. The Global Narcotic Pain Relievers Market, 2011-2021
4.1 The Narcotics Drug Market: Analysis and Forecast, 2011-2021
4.2 Oxycontin Market Forecast, 2011-2021
4.2.1 Development of Oxycontin (Oxycodone)
4.3 Duragesic Market Forecast, 2011-2021
4.3.1Development of Duragesic (Fentanyl)
4.4 Actiq Market Forecast, 2011-2021
4.4.1Development of Actiq (Fentanyl)
4.5 Other Narcotic Agents Market Forecast, 2011-2021
4.6 Total Revenues in the Narcotics Market Will Increase, Despite its Being Crowded
5. The Global Non-Narcotic Pain Relievers Market, 2011-2021
5.1 The Non-Narcotics Market: Analysis and Forecast, 2011-2021
5.2 Aspirin Bayer Market Forecast, 2011-2021
5.2.1 Development of Aspirin Bayer (Acetylsalicylic Acid)
5.3 Efferalgan Market Forecast, 2011-2021
5.3.1 Development of Efferalgan (Paracetamol/Acetaminophen)
5.4 Doliprane (Paracetamol/Acetaminophen) Market Forecast, 2011-2021
5.5 Advil Market Forecast, 2011-2021
5.5.1 Advil (Ibuprofen)
5.6 Tylenol Market Forecast, 2011-2021
5.6.1 Development of Tylenol (Paracetamol/Acetaminophen)
5.7 Other Non-Narcotics Agents Market Forecast, 2011-2021
6. Global Arthritic Pain Relieving Drug Market, 2011-2021
6.1 The Arthritic Pain Market Analysis and Forecast, 2011-2021
6.1.1 Safety Issues for COX-2 Inhibitors
6.2 Celebrex Market Forecast, 2011-2021
6.2.1 Development of Celebrex (Celecoxib)
6.3 Voltaren Market Forecast, 2011-2021
6.3.1Development of Voltaren (Diclofenac)
6.4 Arcoxia Market Forecast, 2011-2021
6.4.1Development of Arcoxia (Etoricoxib)
6.5 Loxonin Market Forecast, 2011-2021
6.5.1 Development of Loxonin (Loxopfrofen)
6.6 Mobic Market Forecast, 2011-2021
6.6.1 Development of Mobic (Meloxicam)
6.7 Other Arthritic Pain Relieving Agents Market Forecast, 2011-2021
6.8 Outlook for the Arthritis Pain Drug Market
7. The Global Migraine Pain Relieving Drug Market, 2011-2021
7.1The Migraine Drug Market Analysis and Forecast, 2011-2021
7.2 Imitrex/Imigran Market Forecast, 2011-2021
7.2.1 Development of Imitrex/Imigran (Sumatriptan)
7.3 Maxalt Market Forecast, 2011-2021
7.3.1 Development of Maxalt (Rizatriptan)
7.4 Zomig Market Forecast, 2011-2021
7.4.1 Development of Zomig (Zolmitriptan)
7.5 Treximet Market Forecast, 2011-2021
7.5.1 Development of Treximet (Naproxen Sodium + Sumatriptan)
7.6 Other Anti-Migraine Agents Market Forecast, 2011-2021
7.7 What Does the Future Hold for Migraine Therapy?
7.8 Unmet Needs in the Treatment of Migraine
8. Neuropathic Pain and Local Anaesthetic Markets, 2011-2021
8.1 Introduction
8.1.1 Anti-Epileptic Drugs Market
8.2 Anti-Epileptic Market Analysis and Forecast, 2011-2021
8.3 Lyrica Market Forecast, 2011-2021
8.3.1 The Development of Lyrica (Pregabalin)
8.4 Topamax Market Forecast, 2011-2021
8.4.1 Development of Topamax (Topiramate)
8.5 Lamictal Market Forecast, 2011-2021
8.5.1 Development of Lamictal (Lamotrigine)
8.6 Other Neuropathic Pain Relieving Agents, 2011-2021
8.7 Local Anaesthetic Market Analysis and Forecast, 2011-2021
8.8 Lidoderm Market Forecast, 2011-2021
8.8.1 Development of Lidoderm (Lidocaine)
8.9 Other Local Anaesthetic Agents Market Forecast, 2011-2021
9. Drivers and Restraints in the Global Pain Relieving Drug Market, 2011-2021
9.1 SWOT Analysis of the Global Pain Relieving Drug Market, 2011-2021
9.2 Market Drivers
9.3 Market Restraints
9.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors
9.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs
9.6 Patients Dependent on Reformulations of Existing Drugs
9.7 The Narcotics Market Suffers from Serious Side Effects
9.8 Risk of Intestinal Bleeding Associated With Use of NSAIDs
9.9 The Unmet Needs in the Treatment of Pain
9.10 How Will Those Findings Affect Commercial Prospects?
9.11 The Future of the Pain Market - Closing Comments
9.11.1 Improved Use of New and Existing Pain Management Therapies
9.11.2 Analgesic Effects of Established Drugs for Other Indications
9.11.3 Personalised Pain Management Therapy
10. Leading National Markets for Pain Relieving Drugs, 2011-2021
10.1 The Pain Drug Market: Regional Sales Breakdown
10.2 Pain Drug Revenues in Major National Markets, 2011-2021
10.2.1 The Pain Drug Market in the US, 2011-2021
10.2.2 The Pain Drug Market in Japan, 2011-2021
10.2.3 The Pain Drug Market in Germany, 2011-2021
10.2.4 The Pain Drug Market in France, 2011-2021
10.2.5 The Pain Drug Market in the UK, 2011-2021
10.2.6 The Pain Drug Market in Spain, 2011-2021
10.2.7 The Pain Drug Market in Italy, 2011-2021
10.2.8 Top 5 EU Markets for Pain Management, 2011-2021
10.2.9 The Pain Drug Market in China, 2011-2021
10.2.10 The Pain Drug Market in India, 2011-2021
10.2.11 Total Revenues from Emerging Economies: India and China, 2011-2021
10.2.12 The Pain Drug Market in the Rest of the World, 2011-2021
10.2.13 Regional Sales Breakdown for Pain Relieving Drugs, 2009
11. The R&D Pipeline for the Treatment of Pain
11.1 The R&D Pipeline for Pain Treatment is Large and Expanding
11.2 The Potential of the Pain Drug Market Has Encouraged R&D
11.3 Innovation Rules for Early-Stage Pipeline Drugs
11.4 The R&D Pipeline for Narcotic Pain Relieving Drugs: Late Stage
11.4.1 Acurox (King, Acura)
11.4.2 Remoxy (King, Pain Therapeutics, DURECT)
11.4.3 BEMA Buprenorphine (BioDelivery Sciences)
11.4.4 Morphine Glucuronide (PAION)
11.4.5 MoxDuo IR (Shire; China Aoxing; QRxPharma)
11.4.6 Probuphine (Titan)
11.4.7 Acuracet (King, Acura)
11.4.8 ARX 02 (Acel Rx)
11.4.9 ARX 03 (Acel Rx)
11.5 The R&D Pipeline for Non Narcotic Drugs: Late Stage
11.5.1 Neosaxitonin (Proteus SA)
11.5.2 ADLEA 4975 (Anesiva; Johns Hopkins University)
11.5.3 OMS 103 HP (Omeros)
11.5.4 Tetrodotoxin (WEX; CK Life Sciences)
11.5.5 Apricoxib (Tragara; Daiichi Sankyo)
11.5.6 AZD 1386 (AstraZeneca)
11.5.7 AZD 2066 (AstraZeneca)
11.5.8 CE 224535 (Pfizer)
11.5.9 Fulranumab (Johnson & Johnson; Takeda; Amgen)
11.5.10 MK 2295 (Ligand; Merck & Co.)
11.6 The R&D Pipeline for Arthritic Pain Relieving Drugs: Late Stage
11.6.1 Famotidine + Ibuprofen (Horizon)
11.6.2 Ibuprofen-PC (PLx Pharma)
11.6.3 Apricoxib (Tragara; Daiichi Sankyo)
11.6.4 CEP 33222 (Cephalon; Acusphere)
11.7 The R&D Pipeline for Migraine Pain Relieving Drugs: Late Stage
11.7.1Garbapentin Enacarbil (GlaxoSmithKline; Astellas; XenoPort)
11.7.2 Zelrix (NuPathe)
11.7.3 LEVADEX (Allergan; MAP Pharmaceuticals)
11.7.4 Perampanel (Eisai)
11.7.5 Talcagepant (Merck & Co.)
11.7.6 Lasmiditan (CoLucid; Eli Lilly)
11.7.7 SB 705498 (GlaxoSmithKline)
11.8 The R&D Pipeline for Neuropathic Pain Relieving Drugs: Late Stage Drugs
11.8.1 Retigabine (GlaxoSmithKline; Valeant; Meda)
11.8.2 Brivaracetum (UCB)
11.8.3 EPLIGA (Dae Woong; Supernus)
11.8.4 Perampanel (Eisai)
11.8.5 Safinamide (Newron; Merck Serono; Pfizer; Merck KGaA)
11.8.6 USL 255 (Upsher-Smith)
11.8.7 Ganaxolone (Marinus; Purdue; Purdue/Mundipharma)
11.8.8 Tonerbersat (Proximagen; Upsher-Smith; GlaxoSmithKline)
11.9 The R&D Pipeline for Local Anaesthetic Drugs: Late Stage
11.9.1 Tetrodotoxin (WEX; CK Life Sciences)
11.9.2 ELADUR (King; DURECT)
11.10 Recent Industry Updates
12. Other Developments in Pain Management
12.1 Cannabinoids and Pain: An Alternative to Opioids?
12.2 Experimentally-Induced Acute Pain
12.3 Post-Surgical Acute Pain
12.4 Chronic Pain
12.5 Sativex
12.5.1 European Phase III trials of Sativex
12.5.2 Sativex Approved for Cancer Pain
12.6 Cannabinoids and Pain: A Lucrative Market?
12.7 The Future of Pain Research
12.8 Advanced Drug Delivery
12.8.1 Delivery of Low-Solubility Drugs
12.8.2 Examples of Low-Solubility Drugs
12.9 Challenges Faced by Novel Painkillers (mAbs)
12.10 Novel Opioid Molecules
13. Opinions from Our Industry Survey
13.1 Dr Jim Winkler, VP Discovery/Translational Biology, Array BioPharma,UK
13.1.1 Views on the Unmet Needs in the World Pain Management Market
13.1.2 Views on Market Growth in the Next 10 Years
13.1.3 Views on Drivers and Restraints in the Pain Management Market
13.1.4 Views on the R&D Pipeline for Pain Management
13.2 Dr Lars Popper, Associate Principal Medical Advisor, Nycomed, Denmark
13.2.1 Views on Unmet Needs in Pain Treatment
13.2.2 Technologies and Strategies for the Discovery of New Pain Relieving Agents
13.2.3 The Pain Relieving Drug Market from the Perspective of the Industry
13.2.4 Views on the R&D Pipeline for Pain Relieving Treatments
14. Conclusions
14.1 The Pain Drug Market Will Achieve Revenue Growth from 2011
14.2 The Neuropathic Pain Market Will Dominate the Pain Drug Sector
14.3 The Narcotics Market Hampered by Concerns
14.4 The Anti-Arthritic Pain Relieving Market Will Grow Rapidly
14.5 The Anti-Migraine Market Will Suffer from Patent Expiry for Leading Products
14.6 Leading National Markets Will Achieve Significant Revenue Growth
14.7 The Pain Drug Market Will Continue to Grow, Despite Challenges
List of Tables
Table 3.1 Global Pain Relieving Drug Market, 2009-2021
Table 3.2 World Revenues ($m) & Market Shares (%) Based on Sub Markets, 2009
Table 3.3 Top Ten Pain Relieving Drugs Revenues ($m), 2009
Table 3.4 Global Pain Relieving Drug Market: Revenues ($m) by Sub Market, 2009-2015
Table 3.5 Global Pain Relieving Drug Market: Revenues ($m) by Sub Market, 2015-2021
Table 3.6 Main Pain Relieving Drugs by Sub-Market: Revenues ($m) and Market Shares (%), 2009
Table 4.1 World Narcotic Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 4.2 World Oxycontin Revenues ($m), 2009-2021
Table 4.3 World Duragesic Revenues ($m), 2009-2021
Table 4.4 World Actiq Revenues ($m), 2009-2021
Table 4.5 World Other Narcotic Drug Revenues ($m), 2009-2021
Table 4.6 World Narcotic Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 5.1 World Non-Narcotic Drug Market Revenues ($m), 2009-2021
Table 5.2 World Aspirin Bayer Revenues ($m), 2009-2021
Table 5.3 World Efferalgan Revenues ($m), 2009-2021
Table 5.4 World Doliprane Revenues ($m), 2009-2021
Table 5.5 World Advil Revenues ($m), 2009-2021
Table 5.6 World Tylenol Revenues ($m), 2009-2021
Table 5.7 World Other Non-Narcotic Drug Revenues ($m), 2009-2021
Table 5.8 World Non-Narcotic Drug Market Revenues ($m), 2009-2021
Table 6.1 World Arthritic Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 6.2 World Celebrex Revenues ($m), 2009-2021
Table 6.3 World Voltaren Revenues ($m), 2009-2021
Table 6.4 World Arcoxia Revenues ($m), 2009-2021
Table 6.5 World Loxonin Revenues ($m), 2009-2021
Table 6.6 World Mobic Revenues ($m), 2009-2021
Table 6.7 World Other Arthritic Drug Revenues ($m), 2009-2021
Table 6.8 World Arthritic Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 7.1 World Migraine Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 7.2 World Imitrex Revenues ($m), 2009-2021
Table 7.3 World Maxalt Revenues ($m), 2009-2021
Table 7.4 World Zomig Revenues ($m), 2009-2021
Table 7.5 World Treximet Revenues ($m), 2009-2021
Table 7.6 World Other Migraine Drug Revenues ($m), 2009-2021
Table 7.7 World Migraine Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 8.1 World Neuropathic Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 8.2 World Lyrica Revenues ($m), 2009-2021
Table 8.3 World Topamax Revenues ($m), 2009-2021
Table 8.4 World Lamictal Revenues ($m), 2009-2021
Table 8.5 World Other Neuropathic Drug Revenues ($m), 2009-2021
Table 8.6 World Neuropathic Pain Relieving Drug Revenues ($m), 2009-2021
Table 8.7 World Local Anaesthetic Drug Revenues ($m), 2009-2021
Table 8.8 World Lidoderm Revenues ($m), 2009-2021
Table 8.9 World Other Local Anaesthetic Drug Revenues ($m), 2009-2021
Table 8.10 World Local Anaesthetic Drug Market Revenues ($m), 2009-2021
Table 9.1 SWOT Analysis of the Global Pain Relieving Drug Market ($m), 2011-2021
Table 10.1 Leading National Market Shares (%) for Pain Management, 2009, 2015 & 2021
Table 10.2 Leading National Market Revenues ($m) for Pain Management ($m), 2009-2021
Table 10.3 US Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.4 Japanese Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.5 German Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.6 French Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.7 UK Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.8 Spanish Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.9 Italian Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.10 Top 5 EU Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.11 Chinese Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.12 Indian Pain Relieving Drug Market Revenues ($m), 2009-2021
Table 10.13 Pain Relieving Drug Market Revenues ($m): China and IndiaCompared, 2009-2021
Table 10.14 Pain Relieving Drug Market Revenues ($m) in the Rest of the World, 2009-2021
Table 10.15 Regional Revenues ($m) and Market Shares (%) for Pain Relieving Drugs, 2009
Table 11.1 Late Stage R&D Pipeline for Narcotic Pain Relieving Drugs, 2011
Table 11.2 Late Stage R&D Pipeline for Non-Narcotic Pain Relieving Drugs, 2011
Table 11.3 Late Stage R&D Pipeline for Arthritic Pain Relieving Drugs, 2011
Table 11.4 Late Stage R&D Pipeline for Migraine Pain Relieving Drugs, 2011
Table 11.5 Late Stage R&D Pipeline for Neuropathic/Epileptic Pain Relieving Drugs, 2011
Table 11.6 Late Stage R&D Pipeline for Local Anaesthetic Drugs, 2011
List of Figures
Figure 3.1 Global Pain Relieving Drug Market Revenues ($m), 2009-2015
Figure 3.2 Global Pain Relieving Drug Market Revenues ($m), 2015-2021
Figure 3.3 World Market Shares (%) by Sub Market, 2009
Figure 3.4 World Market Shares (%) by Sub Market, 2015
Figure 3.5 World Market Shares (%) by Sub Market, 2021
Figure 4.1 World Narcotic Pain Relieving Drug Market Revenues ($m), 2009-2015
Figure 4.2 World Narcotic Pain Relieving Drug Market Revenues ($m), 2015-2021
Figure 4.3 World Oxycontin Revenues ($m), 2009-2021
Figure 4.4 World Duragesic Revenues ($m), 2009-2021
Figure 4.5 World Actiq Revenues ($m), 2009-2021
Figure 4.6 World Other Narcotic Drug Revenues ($m), 2009-2021
Figure 5.1 World Non-Narcotic Drug Market Revenues ($m), 2009-2015
Figure 5.2 World Non-Narcotic Drug Market Revenues ($m), 2015-2021
Figure 5.3 World Aspirin Bayer Revenues ($m), 2009-2021
Figure 5.4 World Efferalgan Revenues ($m), 2009-2021
Figure 5.5 World Doliprane Revenues ($m), 2009-2021
Figure 5.6 World Advil Revenues ($m), 2009-2021
Figure 5.7 World Tylenol Revenues ($m), 2009-2021
Figure 5.8 World Other Non-Narcotic Drug Revenues ($m), 2009-2021
Figure 6.1 World Arthritic Pain Relieving Drug Market Revenues ($m), 2009-2015
Figure 6.2 World Arthritic Pain Relieving Drug Market Revenues ($m), 2015-2021
Figure 6.3 World Celebrex Revenues ($m), 2009-2021
Figure 6.4 World Voltaren Revenues ($m), 2009-2021
Figure 6.5 World Arcoxia Revenues ($m), 2009-2021
Figure 6.6 World Loxonin Revenues ($m), 2009-2021
Figure 6.7 World Mobic Revenues ($m), 2009-2021
Figure 6.8 World Other Arthritic Drug Revenues ($m), 2009-2021
Figure 7.1 World Migraine Pain Relieving Drug Market Revenues ($m), 2009-2015
Figure 7.2 World Migraine Pain Relieving Drug Market Revenues ($m), 2015-2021
Figure 7.3 World Imitrex Revenues ($m), 2009-2021
Figure 7.4 World Maxalt Revenues ($m), 2009-2021
Figure 7.5 World Zomig Revenues ($m), 2009-2021
Figure 7.6 World Treximet Revenues ($m), 2009-2021
Figure 7.7 World Other Migraine Drug Revenues ($m), 2009-2021
Figure 8.1 World Neuropathic Pain Relieving Drug Market Revenues ($m), 2009-2015
Figure 8.2 World Neuropathic Pain Relieving Drug Market Revenues ($m), 2015-2021
Figure 8.3 World Lyrica Revenues ($m), 2009-2021
Figure 8.4 World Topamax Revenues ($m), 2009-2021
Figure 8.5 World Lamictal Revenues ($m), 2009-2021
Figure 8.6 World Other Neuropathic Drug Revenues ($m), 2009-2021
Figure 8.7 World Local Anaesthetic Drug Market Revenues ($m), 2009-2015
Figure 8.8 World Local Anaesthetic Drug Market Revenues ($m), 2015-2021
Figure 8.9 World Lidoderm Revenues ($m), 2009-2021
Figure 8.10 World Other Local Anaesthetic Drug Revenues ($m), 2009-2021
Figure 10.1 Leading National Market Shares (%), 2009
Figure 10.2 Leading National Market Shares (%), 2015
Figure 10.3 Leading National Market Shares (%), 2021
Figure 10.4 US Pain Relieving Drug Market Revenues ($m), 2009-2021
Figure 10.5 Japanese Pain Relieving Drug Market Revenues ($m), 2009-2021
Figure 10.6 US & Japanese Pain Relieving Drug Market Revenues ($m), 2009-2021
Figure 10.7 Top 5 EU Pain Relieving Drug Market Revenues ($m), 2009-2021
Figure 10.8 Pain Relieving Drug Market Revenues ($m): China and IndiaCompared, 2009-2021
Figure 10.9 Rest of the World Pain Market Revenues ($m), 2009-2021
Figure 10.10 Pain Relieving Drug Revenues ($m) in Leading World Markets, 2009-2021
Figure 10.11 Regional Market Shares (%), 2009
Companies Listed
AstraZeneca
Abbott Laboratories
Acura Pharmaceuticals
Acusphere
Acel Rx Pharmaceuticals
Alkermes
Alpharma Pharmaceuticals
Alza Corporation
Allergan
Almirall
Amgen
Anesiva
Anesta Corporation
Apotex
Applied Pharma Research
Astellas Pharma
AstraZeneca
Bayer HealthCare
Biovail Corporation
Bio Delivery Sciences
Boehringer Ingelheim
Bristol Myers Squibb
CeNeS Pharmaceuticals
Cephalon
China Aoxing
CK Life Sciences
Cipher Pharmaceuticals
CoLucid Pharmaceuticals
Cumberland Pharmaceuticals
CyDex Pharmaceuticals
Dae Woong
Daiichi Sankyo
Dr. Reddy's Laboratories
DURECT Corporation
Eisai
Eli Lilly
European Medicines Agency (EMEA/EMA)
Endo Laboratories
Food and Drug Administration (US FDA)
Genentech
GlaxoSmithKline
GW Pharmaceuticals
Horizon Pharma
International Association for the Study of Pain (IASP)
Ikano Therapeutics
Janssen Pharmaceutical
Javelin Pharmaceuticals
Johns Hopkins University
Johnson & Johnson
KemPharm
King Pharmaceuticals
Kowa Pharmaceuticals
Kyorin Pharmaceutical
Ligand Pharmaceuticals
Lundbeck Pharmaceuticals
MAP Pharmaceuticals
Marinus
Meda Pharmaceuticals
Merck & Co.
Merck Serono
Merck KGaA
Mylan Pharmaceuticals
National Institutes of Health (NIH)
Napp Pharmaceutical Group
Nektar Therapeutics
Newron Pharmaceuticals
NicOX
Novartis
NuPathe
Omeros Pharmaceuticals
Pain Therapeutics
PAION
Pfizer
Plethora Solutions
PLx Pharma
Pozen Pharmaceuticals
Purdue Pharma
Proteus SA
Proximagen
QRxPharma
Ranbaxy Laboratories
Ratiopharm
Sanofi-Aventis
Shionogi Pharma
Shire Pharmaceuticals
SK Corporation
SkyePharma
Stada
Supernus Pharmaceuticals
Takeda
Teva Pharmaceutical Industries
Titan Pharmaceuticals
Tragara Pharmaceuticals
Transdermal Pharmaceuticals
UCB Pharma
Ugand
Upsher Smith Pharmaceuticals
US Society for Neuroscience
Valeant Pharmaceuticals
WEX Pharmaceuticals
World Health Organisation (WHO)
Wyeth Pharmaceuticals
XenoPort Pharma
ZARS Pharma
To order this report:
Drug and Medication Industry: World Pain Relieving Drug Market 2011-2021
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article